ArticleBMC infectious diseases2025
Influenza-related invasive pulmonary aspergillosis in an infectious disease ward at a pulmonary referral center in Iran.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning for early screening of influenza A-associated invasive pulmonary aspergillosis in hospitalized patients: a real-world study.Frontiers in cellular and infection microbiology · 2026Article
- Comparative clinical features and outcomes of invasive pulmonary aspergillosis following influenzaFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfluenza-associated invasive pulmonary aspergillosis (IPA) is a known complication of influenza in the intensive care unit (ICU) but limited information is evident for non-ICU patients.
methodsIn this cross-sectional study, we retrospectively collected electronic medical records of all patients admitted to the medical infectious disease ward who had confirmed influenza and met the criteria for invasive aspergillosis. This study recruited patients between September 2023 to May 2024 from the Masih Daneshvari Educational Pulmonary Referral Center in Iran.
resultsAmong 109 patients with confirmed influenza, 10 were diagnosed with IPA. Our findings indicated that the odds of death were significantly higher in patients with IPA compared to those without it (Odds Ratio [OR] = 20.78, 95% Confidence Interval [CI] [2.97 to 145.61], P = 0.005). The rate of bacterial co-infections was also elevated in patients with IPA compared to those without (OR = 4.7, 95% CI [1.22 to 18.01], P = 0.025). Patients with IPA had a greater likelihood of being transferred to the ICU (OR = 3.4, 95% CI [0.77 to 15.2], P = 0.118). They experienced longer hospital stays, with a median duration of 19.5 days (Interquartile Range [IQR] [11.7–26.5]) compared to 7 days (IQR [6–12]) for those without IPA (Z = -3.8, P < 0.001). Furthermore, patients with IPA had a significantly higher likelihood of having underlying lung disease compared to their counterparts without IPA (OR = 67, 95% CI [1.3 to 33.3], P = 0.015).
conclusionsThis study found that IPA is a lethal complication of influenza among non-ICU patients with Influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.